false 0001734750 0001734750 2023-11-15 2023-11-15 iso4217:USD xbrli:shares iso4217:USD xbrli:shares



Washington, DC 20549




Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934


Date of Report (Date of earliest event reported) November 15, 2023


Movano Inc.

(Exact name of registrant as specified in its charter)


Delaware   001-40254   82-4233771

(State or other jurisdiction

of incorporation)

  (Commission File Number)   (IRS Employer
Identification No.)


6800 Koll Center Parkway, Pleasanton, CA   94566
(Address of principal executive offices)   (Zip Code)


Registrant’s telephone number, including area code (415) 651-3172


Not applicable

(Former name or former address, if changed since last report)


Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):


Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)


Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)


Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))


Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))


Securities registered pursuant to Section 12(b) of the Act:


Title of each class   Trading Symbol(s)   Name of each exchange on which registered
Common stock, par value $0.0001 per share   MOVE   The Nasdaq Stock Market LLC


Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).


Emerging growth company


If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.







Item 2.02 Results of Operations and Financial Condition.


On November 15, 2023, Movano Inc. announced its financial results for the quarter ended September 30, 2023. A copy of the press release is being furnished as Exhibit 99 to this Current Report on Form 8-K.


The information in this Current Report on Form 8-K and Exhibit 99 attached hereto is intended to be furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934 (the “Exchange Act”) or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act, except as expressly set forth by specific reference in such filing.


Item 9.01. Financial Statements and Exhibits.


The exhibits to this Current Report on Form 8-K are listed below and incorporated herein by reference.


Exhibit No.   Description
99   Press release, dated November 15, 2023, issued by Movano Inc., furnished herewith.
104   Cover Page Interactive Data File (embedded within the Inline XBRL document)







Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.


  Movano Inc.
Date: November 15, 2023 By: /s/ Jeremy Cogan
  Name:  Jeremy Cogan
  Title: Chief Financial Officer





Exhibit 99.1



Movano Health Provides Business Update and Reports Third Quarter 2023 Financial Results


Conference call begins at 8:30 a.m. Pacific time today


Pleasanton, Calif. – November 15, 2023 – Today, Movano Health (Nasdaq: MOVE), a purpose-driven healthcare solutions company at the intersection of medtech and consumer devices and makers of the Evie Ring, reported financial results for the three months ending September 30, 2023 and provided a business update.


Key highlights from the third quarter and recent weeks include:


The Company will begin selling its first product, the Evie Ring, on November 20, ahead of Black Friday. Customers will be able to place an order for the Evie Ring exclusively through https://eviering.com/ for $269 and no additional subscription fees or monthly costs. Customers can elect to receive a complimentary sizing kit to find the right fit. The Company expects to begin shipping rings to customers before the end of the year. In order to drive sales of the Evie Ring, Movano Health has been executing a comprehensive marketing campaign. The Company launched a new commercial website for the Evie Ring on November 6, which offers a detailed and interactive look at the female first features and benefits of the Evie solution. Since then, the site has seen more than 200,000 visits. Movano Health’s marketing campaign is focused on converting its engaged lead list of over 120,000 consumers and driving new conversion traffic to the site throughout the Q4 2023 holiday shopping period and beyond by leveraging press reviews, influencer content and new creative.


In a recent 44-person blood pressure clinical study, Movano Health’s proprietary 4 x 6.7 mm System-on-a-Chip (SoC) and prototype solution demonstrated a level of accuracy within the standards recognized by the FDA for blood pressure monitoring devices. Since implementing the Company’s proprietary SoC into clinical studies, which Movano Health spent over five years developing and miniaturizing, the Company has seen a material improvement in the accuracy of its blood pressure measurements.  Movano Health is planning additional multi-week clinical trials both in house and with third party investigators to determine whether periodic calibration is required and refine its AI models on an individual patient basis. Subsequently, Movano Health intends to conduct a pivotal trial for its 510(k) submission to the FDA to commercialize a cuffless blood pressure wearable device.


Following the submission of its 510(k) application to the FDA for the Evie Ring’s pulse oximeter in July 2023, Movano Health has since received a letter from the FDA requesting additional information, which was in line with the Company’s expectations. The Company has been in communication with the agency and plans to submit its formal reply letter to the FDA in Q1 2024. If clearance is received, it has the potential to unlock a significant enterprise opportunity with partners across healthcare.


  Movano Health has priced a $3.6 million underwritten public offering of 4,235,304 shares of its common stock. The public offering price, before the underwriters’ discount and commissions, for each share of common stock is $0.85. All of the securities in the underwritten public offering are being sold by the Company. The Company has granted the underwriter a 30-day option to purchase up to an additional 15% of shares of common stock sold in the offering at the public offering price, less the underwriting discount. The offering is expected to close on November 17, 2023.





“We believe we’ve set the stage for the successful introduction of Evie into the market on November 20 and are excited to embark on this new phase of our journey as we shift from pre-revenue to a revenue-generating company,” said John Mastrototaro, CEO of Movano Health.  “The timing for such a product couldn’t be better with increased interest in medical grade technologies for home use and a strong focus on women’s health and empowerment.  With its thoughtful design, accurate data and meaningful insights, we believe the Evie Ring holds immense potential for our company, our stakeholders and the health and wellness of our future customers.”


“In addition to focusing on the launch of the Evie Ring, we are also building a high-value healthcare solutions roadmap to commercialize cuffless blood pressure and noninvasive glucose monitoring solutions that leverage our SoC,” said Michael Leabman, founder and CTO of Movano Health. “During a Q3 2023 blood pressure clinical study, our proprietary SoC and prototype solution demonstrated a level of accuracy within the standards recognized by the FDA for blood pressure monitoring devices. This was a significant breakthrough for us, and while there’s more work to do before we can file for FDA clearance, we’ve taken a major step forward on the path to commercialization of a cuffless blood pressure monitoring device.”


Third Quarter 2023 Financial Results and Recent Capital Markets Activity 


Movano Health reported a net loss of $9.0 million and a loss of $(0.18) per basic and diluted share, in the third quarter of 2023, compared with a net loss of $8.6 million and a loss of $(0.26) per basic and diluted share, in the third quarter of 2022.


  The Company reported an operating loss of $9.1 million in the third quarter of 2023 compared to an operating loss of $8.7 million in the third quarter of 2022.


  Movano Health is a development stage company and, as such, the Company did not generate revenue in either the second quarter of 2023 or the second quarter of 2022.


  The Company had $7.7 million in cash and cash equivalents as of September 30, 2023, compared to $10.8 million in cash and cash equivalents as of December 2022. Pro forma for the expected net proceeds of the equity offering announced on November 15, the Company had $10.8 million in cash and cash equivalents as of September 30, 2023.


  The total number of shares outstanding was 50,805,951 as of September 30, 2023.


Conference Call and Webcast


Management will host a conference call and live audio webcast to discuss these results and provide a business update today at 8:30 a.m. PST (11:30 a.m. EST).


Attendees can access the live webcast here or on the investors section of Movano Health’s website at https://ir.movano.com. The conference call can be accessed by dialing 1-877-407-0989 (domestic) or +1- 201-389-0921 (international). Attendees can also use the Call Me link, in which they will be dialed in to the conference call instantly on the number provided with no hold time. An archived webcast will be available on Movano Health’s website approximately one hour after the completion of the event and for two years thereafter.





About Movano Health


Founded in 2018, Movano Inc. (Nasdaq: MOVE) dba Movano Health is developing a suite of purpose-driven healthcare solutions to bring medical-grade, high-quality data to the forefront of consumer health devices. Featuring modern form factors, Movano Health’s devices capture a comprehensive picture of a person’s vital health information and uniquely translate the data into personalized and intelligent insights that empower consumers to live healthier and more balanced lives. Movano Health’s end-to-end solutions will soon enable consumers and their healthcare professionals to utilize daily medical-grade data as a tool to proactively monitor and manage health outcomes. For more information on Movano Health, visit https://movanohealth.com/.


Forward Looking Statements


This press release contains forward-looking statements concerning our expectations, anticipations, intentions, beliefs, or strategies regarding the future. These forward-looking statements are based on assumptions that we have made as of the date hereof and are subject to known and unknown risks and uncertainties that could cause actual results, conditions, and events to differ materially from those anticipated. Therefore, you should not place undue reliance on forward-looking statements. Examples of forward-looking statements include, among others, statements we make regarding the anticipated closing of the public offering, plans with respect to commercial launch of the Evie Ring, anticipated FDA clearance for the Evie Ring and other products in development, expected future operating results; product development and features, product releases, clinical trial, and regulatory initiatives; our strategies, positioning and expectations for future events or performance. Important factors that could cause actual results to differ materially from those in the forward-looking statements are set forth in our most recent Annual Report on Form 10-K and any subsequent Quarterly Reports on Form 10-Q, and in our other reports filed with the Securities and Exchange Commission, including under the caption “Risk Factors.” Any forward-looking statement in this release speaks only as of the date of this release. We undertake no obligation to publicly update any forward-looking statement, whether written or oral, that may be made from time to time, whether as a result of new information, future developments or otherwise.


Investor Contact:



J. Cogan, CFA






Movano Inc.


(In thousands)



   September 30,   December 31, 
   2023   2022 
Current assets:        
Cash and cash equivalents  $7,669   $10,759 
Payroll tax credit, current portion   250    379 
Vendor deposits   601    103 
Prepaid expenses and other current assets   657    405 
Total current assets   9,177    11,646 
Property and equipment, net   363    443 
Payroll tax credit, noncurrent portion   667    667 
Other assets   386    487 
Total assets  $10,593   $13,243 
Current liabilities:          
Accounts payable  $1,955   $557 
Other current liabilities   3,578    4,421 
Total current liabilities   5,533    4,978 
Noncurrent liabilities:          
Early exercised stock option liability   47    136 
Other noncurrent liabilities   69    214 
Total noncurrent liabilities   116    350 
Total liabilities   5,649    5,328 
Stockholders’ equity:          
Common stock   5    3 
Additional paid-in capital   123,361    103,009 
Accumulated deficit   (118,422)   (95,097)
Total stockholders’ equity   4,944    7,915 
Total liabilities and stockholders’ equity  $10,593   $13,243 





Movano Inc.

Condensed Consolidated Statements of Operations and Comprehensive Loss

(in thousands, except share and per share data)



   Three Months Ended
September 30,
   Nine Months Ended
September 30,
   2023   2022   2023   2022 
OPERATING EXPENSES:                
Research and development  $5,636   $5,146   $13,701   $13,849 
Sales, general and administrative   3,443    3,511    9,965    8,592 
Total operating expenses   9,079    8,657    23,666    22,441 
Loss from operations   (9,079)   (8,657)   (23,666)   (22,441)
Other income (expense), net:                    
Interest and other income, net   117    55    341    39 
Other income (expense), net   117    55    341    39 
Net loss  $(8,962)  $(8,602)  $(23,325)  $(22,402)
Net loss  $(8,962)  $(8,602)  $(23,325)  $(22,402)
Other comprehensive income (loss):                    
Change in unrealized loss on available-for-sale securities       7        (3)
Total comprehensive loss  $(8,962)  $(8,595)  $(23,325)  $(22,405)
Net loss per share, basic and diluted  $(0.18)  $(0.26)  $(0.53)  $(0.68)
Weighted average shares used in computing net loss per share, basic and diluted   50,711,449    32,949,649    43,818,011    32,829,940